Literature DB >> 16595039

A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer.

Janice M Walshe1, Neelima Denduluri, Arlene W Berman, Douglas R Rosing, Sandra M Swain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16595039     DOI： 10.3816/CBC.2006.n.009

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN： 1526-8209            Impact factor:   3.225


× No keyword cloud information.
  12 in total

Review 1.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Authors:  Pravin T P Kaumaya; Kevin Chu Foy
Journal:  Future Oncol       Date:  2012-08       Impact factor: 3.404

Review 3.  Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.

Authors:  Anna Emde; Wolfgang J Köstler; Yosef Yarden
Journal:  Crit Rev Oncol Hematol       Date:  2010-10-15       Impact factor: 6.312

4.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

5.  Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.

Authors:  G Brockhoff; B Heckel; E Schmidt-Bruecken; M Plander; F Hofstaedter; A Vollmann; S Diermeier
Journal:  Cell Prolif       Date:  2007-08       Impact factor: 6.831

Review 6.  HER2-positive breast cancer: current and future treatment strategies.

Authors:  Ryan H Engel; Virginia G Kaklamani
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Targeted Therapies for Brain Metastases from Breast Cancer.

Authors:  Vyshak Alva Venur; José Pablo Leone
Journal:  Int J Mol Sci       Date:  2016-09-13       Impact factor: 5.923

8.  Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Authors:  M K Robinson; K M Hodge; E Horak; A L Sundberg; M Russeva; C C Shaller; M von Mehren; I Shchaveleva; H H Simmons; J D Marks; G P Adams
Journal:  Br J Cancer       Date:  2008-10-07       Impact factor: 7.640

9.  A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.

Authors:  G Attard; J Kitzen; S P Blagden; P C Fong; L C Pronk; J Zhi; G Zugmaier; J Verweij; J S de Bono; M de Jonge
Journal:  Br J Cancer       Date:  2007-11-13       Impact factor: 7.640

10.  Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability.

Authors:  Emma L Wilkinson; James E Sidaway; Michael J Cross
Journal:  Biol Open       Date:  2016-10-15       Impact factor: 2.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.